课题基金 / 基金详情

Development of new agents that regulate cellular signal transduction

Development of new agents that regulate cellular signal transduction
开发调节细胞信号转导的新药物
批准号:
15208012
负责人:
OHIGASHI Hajime
金额:
$28.45万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2006

项目摘要

项目成果

OHIGASHI Hajime的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Protein kinase C (PKC) isozymes are major receptors of tumor-promoting phorbol esters. They contain two cysteine-rich C1 domains (C1A, C1B), both of which are candidates for phorbol 12,13-dibutyrate (PDBu) binding sites. To investigate the mechanism of tumor promotion in molecular level, the C1 peptides corresponding to the C1 domains of all PKC isozymes were synthesized, and their dissociation constants for PDBu were measured. The resultant C1 peptide library was used to screen for new ligands with PKC isozyme and C1 domain selectivity to find that indolactam-V (IL-V) is a promising lead compound.We verified that the indole ring of IL-V could be involved in the CH/πinteraction with Pro-11 of the C1B domain of PKCδ using its mutant peptide, in which the CH/π interaction was inhibited by substitution of the hydrogen atom with a fluorine atom at position 4 of Pro-11. IL-V showed about a 10 times lower binding affinity to the mutant peptide compared to the wild-type peptide, suggesting th … More at the CH/π interaction could play a pivotal role on the binding of IL-V to the PKCδ C1B domain. On the other hand, benzolactam-V8 (BL-V8), with the benzene ring instead of the indole ring of IL-V, might lack the CH/π interaction. The low binding affinity of BL-V8 could be enhanced by the effective formation of the CH/n interaction as exemplified by the synthesis of naphtholactam-V8. Based on the difference among the CH/π interaction in PKC isozymes, 1-hexyl-indolactma-V10 and 8-octyl-benzolactam-V9 with potent selectivity for novel PKC isozymes (δ,ε,η,θ) that play significant roles in tumor promotion were developed. Moreover, a simplified analogue of tumor-promoting aplysiatoxin with less hydrophobicity was design-synthesized and shown to translocate PKCδ from cytosol to nuclear membrane like bryostatin 1 with anti-neoplastic activity.Recently, new phorbol ester receptors other than PKC (n-chimaerins, Unc-13s, and RasGRPs) have been reported. We unambiguously demonstrated that diacylglycerol kinase (DGK) γ and β are new targets of tumor-promoting phorbol esters by synthesizing the C1 peptides of all DGK isozymes. Less
期刊论文(62)
专著(0)
科研奖励(0)
会议论文
Development of new medicinal leads based on the CH/π interaction.
基于 CH/π 相互作用开发新的药物先导化合物。
DOI: --
发表时间: 2006
期刊: Pharmacia 42 (5)
影响因子: --
作者: [Hiradate, S., (Hiradate, S.), K.Irie]
通讯作者: K.Irie
DOI: --
发表时间: 2004
期刊: 化学と生物 42・1
影响因子: --
作者: [Oguchi, R., K.Hikosaka, T.Hiura, T.Hirose, 入江 一浩]
通讯作者: 入江 一浩
Design and synthesis of 8-octyl-benzolactam-V9, the selective activator for PKCε and η
PKCε 和 η 选择性激活剂 8-辛基-苯并内酰胺-V9 的设计与合成
DOI: --
发表时间: 2006
期刊: Journal of Medicinal Chemistry 49・9
影响因子: --
作者: [Miyake, H., Yu Nakagawa]
通讯作者: Yu Nakagawa
CH/π 相互作用を利用した薬剤開発
利用 CH/π 相互作用进行药物开发
DOI: --
发表时间: 2006
期刊: ファルマシア 42・5
影响因子: --
作者: [Ohtsu, K, 入江 一浩]
通讯作者: 入江 一浩
20
    Rational design of mixing ratio of food-derived anti-inflammatory factors based on molecular mechanisms.
    • 批准号:
      23658119
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $1.5万
    • 财政年份:
      2011
    • 负责人:
      OHIGASHI Hajime
    • 依托单位:
    Exploration of anti-inflammatory food factors from plant diets, and chemical classification of such factors based on their action mechanisms
    • 批准号:
      20580139
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2008
    • 负责人:
      OHIGASHI Hajime
    • 依托单位:
    Prevention of colon cancer with the de novo suppressants of iNOS and COX-2 expressions
    • 批准号:
      12556018
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.68万
    • 财政年份:
      2000
    • 负责人:
      OHIGASHI Hajime
    • 依托单位:
    Ecochemical study on the medicinal plant use of primates in the wild
    • 批准号:
      08306005
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $9.79万
    • 财政年份:
      1996
    • 负责人:
      OHIGASHI Hajime
    • 依托单位:
    国内基金
    海外基金
    Bryostatin逆转耗竭型CD8+T细胞表观遗传修饰在恶性胸腔积液中的治疗作用及其机制研究
    • 批准号:
      82300121
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2023
    • 负责人:
      赵满芝
    • 依托单位:
    天然产物Bryostatin5的克级规模的全合成
    • 批准号:
      CSTB2023NSCQ-MSX0240
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2023
    • 负责人:
      徐标
    • 依托单位: